The a16z Show Man, Mosquito, Malaria Vaccine
May 2, 2021
Rajeev Venkayya, president of Takeda's Global Vaccine Business Unit with a rich background in vaccine delivery, joins Jorge Conde, an a16z bio partner expert in infectious diseases. They discuss a groundbreaking malaria vaccine achieving 75% efficacy, the implications for vulnerable populations, and advancement through mRNA technology. The conversation delves into the disparity in vaccine development between wealthy and poorer nations and the ongoing struggle against malaria, highlighting challenges, innovations, and the path to widespread use.
AI Snips
Chapters
Transcript
Episode notes
Vaccine Breakthrough
- A highly efficacious vaccine against a parasite like malaria is a significant achievement, given the parasite's complex nature.
- This breakthrough highlights the importance of long-term research, even with "old world" technologies.
Resource Disparity
- Tropical diseases disproportionately affect poorer countries, potentially hindering research and development efforts.
- Sonal Chokshi and Jorge Conde question if faster progress would have been made if these diseases were prevalent in richer nations.
Childhood Malaria
- Sonal Chokshi recounts childhood experiences with mosquito bites and malaria, highlighting the prevalence of the disease.
- She mentions spitting out the bitter antimalarial medication, leading to her contracting malaria.